Kiwi Extract Cardio- Protective Agent
The invention relates to active fraction from a kiwi fruit (Actinidia)extarct, where the size of the molecules in the active fraction being less than 1000 daltons characterized as being stable and retaining inhibition of platelet aggregation angiotensin converting enzyme activity and further improving or maintaining cardiovascular health. This kiwi fruit extract when consumed is expected to improve blood flow and lower blood pressure, the important risk factors for heart disease. The fraction of the present invention may be incorporated in dietary supplement, formulated with pharmaceutical carriers such as starch, sucrose or lactose in tablets, pills, capsules, etc., syrups or food stuff. The invention further relates to method of producing a stable and biologically active Actinidia extract fraction comprising the steps of producing an Actinidia extract; heating the Actinidia extract to 70 to 100 degree celsius for more than five minutes so that the extract retains biological activity during storage; and processing the extract by ultrafiltration either before or after heating.
- Inhibits platelet aggregation thus improves blood flow and blood thinning.
- Inhibits angiotensin converting enzyme thus lowers blood pressure.
- An active fraction with an enhanced shelf-life of at least 1 year at 4
- No side effects.
Patent Pending in India, USA, New zealand, Japan, China, Canada.
Send download link to email.
Available for exclusive and non-exclusive license marketing, manufacturing, selling and joint developmental activities.
Stage of Developments
Developed exclusively by “University of OSLO “ and further already commercialized successfully in Europe. The inventor has an exclusive marketing, selling and manufacturing right in India. Hence, all kinds of business interests are sought.
The Indian pharma industry, which is expected to grow over 15 per cent per annum between 2015 and 2020, will outperform the global pharma industry, which is set to grow at an annual rate of 5 per cent between the same periods. The market is expected to grow to US$ 55 billion by 2020, thereby emerging as the sixth largest pharmaceutical market globally by absolute size.
India’s biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US$ 100 billion by 2025.